Estimating the long-term treatment benefits of sacubitril-valsartan

New England Journal of Medicine

Volumn 373, Issue 23, 2015, Pages 2289-2290

  Claggett, Brian ^a   Packer, Milton ^b   McMurray, John J V ^c   Swedberg, Karl ^d   Rouleau, Jean ^e   Zile, Michael R ^f   Jhund, Pardeep ^c   Lefkowitz, Martin ^g   Shi, Victor ^g   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DRUG COMBINATION; TETRAZOLE DERIVATIVE; VALSARTAN;

AGE DISTRIBUTION; CLINICAL TRIAL (TOPIC); DEATH; DRUG EFFICACY; EVENT FREE SURVIVAL; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; LETTER; LIFE EXPECTANCY; LONG TERM SURVIVAL; PRIORITY JOURNAL; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; AGED; CAUSE OF DEATH; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; CAUSE OF DEATH; DRUG COMBINATIONS; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; LIFE EXPECTANCY; MIDDLE AGED; TETRAZOLES; VALSARTAN;

EID: 84948844086     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1509753     Document Type: Letter

References (5)

1. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
2. Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol 2005; 162: 975-82.
3. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997; 145: 72-80.
4. Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol 2014; 32: 2380-5.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.